Compare · LLY vs NGNE
LLY vs NGNE
Side-by-side comparison of Eli Lilly and Company (LLY) and Neurogene Inc. (NGNE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and NGNE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.33T, about 2492.7x NGNE ($532.5M).
- LLY has been more active in the news (29 items in the past 4 weeks vs 3 for NGNE).
- LLY has more recent analyst coverage (25 ratings vs 8 for NGNE).
- Company
- Eli Lilly and Company
- Neurogene Inc.
- Price
- -
- -
- Market cap
- $1.33T
- $532.5M
- 1M return
- +23.23%
- -
- 1Y return
- +55.28%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 29
- 3
- Recent ratings
- 25
- 8
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest LLY
- EVP, CS&PO & Pres. LRL Skovronsky Daniel gifted 119 shares, decreasing direct ownership by 0.07% to 159,953 units (SEC Form 4)
- EVP, GC & Secretary Hakim Anat sold $7,012,600 worth of shares (5,000 units at $1,402.52) as part of a pre-agreed trading plan (SEC Form 4)
- EVP & CFO Montarce Lucas converted options into 1,610 shares and covered exercise/tax liability with 678 shares, increasing direct ownership by 6% to 17,191 units (SEC Form 4)
- EVP & Pres., Mfg. Operations Hernandez Edgardo converted options into 2,530 shares and covered exercise/tax liability with 1,123 shares, increasing direct ownership by 3% to 47,490 units (SEC Form 4)
- EVP, Chief People Officer Dozier Eric converted options into 2,300 shares and covered exercise/tax liability with 1,019 shares, increasing direct ownership by 9% to 15,520 units (SEC Form 4)
- EVP & President, Card Met Hlth Custer Kenneth L. converted options into 3,220 shares and covered exercise/tax liability with 1,425 shares, increasing direct ownership by 18% to 11,935 units (SEC Form 4)
- EVP, President LLY Imm Brown Adrienne S converted options into 2,530 shares and covered exercise/tax liability with 1,099 shares, increasing direct ownership by 17% to 9,894 units (SEC Form 4)
- SEC Form 10-Q filed by Eli Lilly and Company
- SEC Form 8-K filed by Eli Lilly and Company
- Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio
Latest NGNE
- Neurogene to Participate in Upcoming Investor Conferences
- Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome
- Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress
- Analyst initiated coverage on Neurogene with a new price target
- SEC Form SCHEDULE 13G filed by Neurogene Inc.
- SEC Form SCHEDULE 13G filed by Neurogene Inc.
- Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Chief Executive Officer Mcminn Rachel exercised 756 shares at a strike of $25.32, increasing direct ownership by 0.06% to 1,345,063 units (SEC Form 4)
- Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference
- Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)